All In Biotech

Drug Trial Radar · NCT00023452

Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection

TBTC Study 26: Effectiveness and Tolerability of Weekly Rifapentine/Isoniazid for 3 Months Versus Daily Isoniazid for 9 Months for the Treatment of Latent Tuberculosis Infection

Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 8,053 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

8,053

Actual

Start

Jun 2001

Primary completion

Oct 2010

Study completion Sep 2013

Sponsor

Sponsor type
Federal agency
Collaborators
US Department of Veterans Affairs
First posted
Sep 10, 2001

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open-label, multi-center, Phase III clinical trial to compare the effectiveness and tolerability of a three-month (12-dose) regimen of weekly rifapentine and isoniazid (3RPT/INH) to the effectiveness of a nine-month (270-dose)regimen of daily isoniazid (9INH) to prevent tuberculosis (TB) among high-risk tuberculin skin-test reactors, including children and HIV-infected persons, who require treatment of latent TB infection (LTBI).

Conditions

  • Tuberculosis

Interventions

  • RPT + INH once weekly for 3 months given by DOTDrug

    Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons \> 50.0 kg. For persons \< 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg. PLUS Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if \> 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2-11 years old. Therapy will be given by Directly Observed Therapy (DOT).

  • Isoniazid (INH) daily for 9 monthsDrug

    Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Rate of Culture-Confirmed TB Disease in Participants ≥18 Years of Age AND Culture-Confirmed or Probable (Clinical) TB Disease in Participants Less Than [<]18 Years of Age at 33 Months After EnrollmentTime frame: Baseline up to Month 33

Locations

26 sites in 4 countries. Site status is shown where the registry gives one.

  • Central Arkansas Veterans Health System

    Little Rock, Arkansas

  • LA County/USC Medical Center

    Los Angeles, California

  • UCSD Medical Center

    San Diego, California

  • University of California, San Francisco

    San Francisco, California

  • Denver Department of Public Health and Hospitals

    Denver, Colorado

  • Washington, D.C. VAMC

    Washington D.C., District of Columbia

  • Emory University, Department of Medicine

    Atlanta, Georgia

  • Chicago VA Medical Center (Lakeside)

    Chicago, Illinois

  • Hines VA Medical Center

    Hines, Illinois

  • Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Boston Medical Center

    Boston, Massachusetts

  • New Jersey Medical School

    Newark, New Jersey

  • Columbia University/Presbyterian Medical Center

    New York, New York

  • Harlem Hospital Center

    New York, New York

  • Carolinas Medical Center

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of North Texas Health Science Center

    Fort Worth, Texas

  • Michael Debakey Veterans Affairs Medical Center

    Houston, Texas

  • Audi L. Murphy VA Hospital

    San Antonio, Texas

  • Seattle King County Health Department

    Seattle, Washington

  • Universidade Federal do Rio de Janeiro

    Rio de Janeiro, Brazil

  • University of British Columbia

    Vancouver, British Columbia, Canada

  • University of Manitoba

    Winnipeg, Manitoba, Canada

  • Montreal Chest Institute McGill University

    Montreal, Quebec, Canada

  • Agencia de Salut Publica

    Barcelona, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.